This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Analysts' Actions: JNJ FNFG WLL CA VRTX

NEW YORK (TheStreet) -- CHANGE IN RATINGS

CA (CA) was downgraded from buy to neutral at Mizuho. $25 price target. CEO could change the product development process, which might cause near-term disruptions, Mizuho said.

F5 Networks (FFIV) was downgraded to hold at TheStreet Ratings.

First Niagara (FNFG) was upgraded to outperform at KBW. $10.50 price target. New CEO could prove to be an inflection point for the company, Keefe, Bruyette & Woods said.

Johnson & Johnson (JNJ) was downgraded to neutral from overweight at J.P. Morgan. $83 price target. Valuation call.

Juniper Networks (JNPR) was upgraded at Argus to buy from hold. $22 price target. Earnings recovery is finally underway, Argus said.


L-3 Communications (LLL) was downgraded at J.P. Morgan to underweight from neutral. Company is most at risk from sequestration cuts, J.P. Morgan said.

Vail Resorts (MTN) was downgraded at Credit Suisse to neutral from outperform. $64 price target. Valuation call, as the stock is up 44% over the past year, Credit Suisse said.

Northrop Grumman (NOC) was upgraded at J.P. Morgan to equal-weight from underweight. Valuation call, J.P. Morgan said.

Public Service (PEG) was downgraded at Argus to hold from buy. Valuation call, as the stock is approaching the previous $35 price target, Argus said.


RDA Microelectronics (RDA) was downgraded to hold at TheStreet Ratings.

Vertex Pharmaceuticals (VRTX) was initiated with a hold rating at Canaccord. Valuation call, based on a $55 price target.

Whiting Petroleum (WLL) was upgraded to overweight at J.P. Morgan. Valuation call, given the company's better outlook, J.P. Morgan said.

STOCK COMMENTS/EPS CHANGES

Apple (AAPL) estimates were increased at Canaccord Genuity through 2014. Company is seeing higher iPhone 4 and 4S sales, and new products should continue to drive demand. Buy rating and $600 price target.

AstraZeneca (AZN) estimates were cut at Leerink Swann through 2014. Cautious feedback for Fostamatinib lowers the chance for FDA approval, Leerink Swann said.

Daimler (DDAIF) price target and estimates were reduced at UBS. First-quarter guidance was worse than expected on weak markets (Germany) and wholesale sales, driving a reduction in earnings estimates, said UBS. The price target goes to $70.22.

Hanesbrands (HBI) price target and estimates were increased at Citigroup. The price target was increased to $54 after the company initiated a dividend which will attract new investors, said Citigroup. Earnings estimates for 2013 were increased given a better-than-expected first quarter result, Citigroup added.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs